# Stage 09 — Coding Interpretation Validation Summary

## Overview

Stage 09 applies deterministic, rule-based logic to classify coding variants into prioritization-ready categories.

---

## Key Metrics

- total coding variants: ~27,486  
- rare variants: ~1,335  
- loss-of-function variants: ~789  
- missense variants: ~11,573  

---

## Interpretation Label Distribution

- common / low-support: ~25,169  
- rare / LOF candidates: ~1,121  
- uninterpretable: ~1,196  

---

## Key Observations

- most coding variants are common and low-impact  
- rare and high-impact variants are uncommon  
- a subset remains uninterpretable due to limited annotation  

---

## Functional Impact

- synonymous and missense variants dominate  
- loss-of-function variants are rare  

---

## Clinical Evidence

- majority of variants lack clinical annotation  
- some variants are labeled benign or VUS  
- pathogenic annotations exist but require context  

---

## Key Insight

> Variant interpretation must integrate multiple dimensions:

- frequency  
- functional impact  
- clinical annotation  

No single metric is sufficient.

---

## Important Considerations

- HG002 is a healthy benchmark genome  
- candidate labels do not imply disease  
- interpretation is probabilistic, not diagnostic  

---

## Role in Pipeline

Stage 09 produces:

- prioritized candidate variants  
- structured labels for downstream ranking (Stage 11)

---

## Conclusion

Stage 09 successfully:

- reduces coding variants to interpretable subsets  
- identifies rare and high-impact candidates  
- preserves uncertainty where appropriate  

---

## Bottom Line

> Stage 09 converts annotated variants into prioritization-ready evidence without overinterpreting biological significance.